Coupling and uncoupling of tumor immunity and autoimmunity. - Wikidata - awgldk - TriplyDB

Coupling and uncoupling of tumor immunity and autoimmunity.

Coupling and uncoupling of tumor immunity and autoimmunity.

http://www.wikidata.org/entity/Q36375693

about

ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 Evidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidity Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen.Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.Immunologic functions as prognostic indicators in melanoma Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma Role of TGF-beta in immune-evasion of cancer.Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".Autoimmune melanocyte destruction in vitiligo.Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen.Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response.Optimization of a self antigen for presentation of multiple epitopes in cancer immunity Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.Multiple pathways to tumor immunity and concomitant autoimmunity.CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.Enhanced responses to tumor immunization following total body irradiation are time-dependent Evidence for an autoimmune pathogenesis of vitiligo.Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.Immune recognition of self in immunity against cancer.Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.Cytokines in cancer immunity and immunotherapy.Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

P2860

Q24531314-A2850EFD-2459-4F94-9F1F-D11C17246A03 Q24604091-BAEFC5A4-E1BB-4558-9BC6-5B388D5B7753 Q24684238-4DCBA099-A82D-4195-A178-9752D092D607 Q24804837-585A6204-EB18-4C84-9715-11B02875AD17 Q26738680-DA5E640B-97F0-45BA-BD26-2CFC85DA47D9 Q28116224-220F6173-4D5C-4E27-9B11-6F550AD6FD20 Q28360452-DCB64A93-F004-44FE-B113-2F0103E2E1B6 Q30715508-4F49F0AA-6AEF-4803-9E4C-3BAA87361A41 Q33606137-2E69FE54-6AE2-449A-AABE-B37A701E8381 Q33689478-97E6B980-FA2A-40B8-96FF-9345951B6556 Q33713435-D746CE58-54C3-4C01-AE32-F7782B5627AA Q33713956-D84436B6-AD43-4632-A95F-8C1ADF283EB0 Q33835011-06DC651A-7D3D-41C9-9324-C8D15FCF07E0 Q33924781-6588ABDE-D248-4AD3-8E08-3E28378319DF Q34136492-8682A760-8A62-44A4-9BC7-0C5EDB2E36EA Q34276512-4A919D50-53BA-44B4-9647-DAB40376A9BB Q34335855-B80CA5A5-5150-442E-BFA7-3AF0D9953EF4 Q34360174-DC946C21-B201-4967-8930-398865E26654 Q34422330-18879AB5-36F0-424B-A718-DECEE0112572 Q34482074-EF770D04-3DBC-423B-932A-087446A5A59B Q34522301-BD3FBBFD-1200-450B-890B-EE9FCBA16AC6 Q34537491-B6CFBC1E-564B-4801-989D-7A4102F83C96 Q34561877-1F846362-A7A5-4C9E-A127-B5C131CD68DC Q34703631-DF0C903E-8231-4613-8EEE-AD311CC17F0C Q34703643-8A9813EB-0AD8-4DD8-BE8B-164715A8203A Q34792069-74150366-3643-45A3-A136-697521934A4B Q34795354-3AB255B8-99F5-4D9B-8F68-CCA2967DC1F5 Q35005930-68D57B13-E7FE-46F1-98CC-674D892857AD Q35005947-7E198484-0590-4146-86CB-47CCEE694BD7 Q35048637-6E6A023D-0D45-44DD-9D87-08855CD91EEB Q35070312-56F0FB9A-D38A-4815-8A79-4538E8946810 Q35080073-82A77814-8946-4FE3-9959-B61C215374CA Q35146595-DEF920C8-FA1C-44D3-94F7-7A8CE96594A0 Q35809463-7445F395-6B9B-4F1F-9816-710C3CAEFB31 Q35864865-F774EF9D-426E-4FB7-BDA1-41B5AD06B9FC Q35948223-D1D4D00F-20C5-43C4-A5AF-BC4F95B9E5EA Q35951855-FBED1419-CA74-4A61-B8C3-64953F2C0E83 Q36198661-F97C1A63-E2A7-426F-A3AF-CF5018666C8B Q36369502-D3D79ED6-9034-4B9C-B280-3DCC678EBBE8 Q36371632-CDAFE835-C6F8-4C62-83C7-810FC8196B71

P2860

Coupling and uncoupling of tumor immunity and autoimmunity.

http://www.wikidata.org/entity/Q36375693

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh

1999年學術文章

@zh-hant

name

Coupling and uncoupling of tumor immunity and autoimmunity.

@ast

Coupling and uncoupling of tumor immunity and autoimmunity.

@en

type

label

Coupling and uncoupling of tumor immunity and autoimmunity.

@ast

Coupling and uncoupling of tumor immunity and autoimmunity.

@en

prefLabel

Coupling and uncoupling of tumor immunity and autoimmunity.

@ast

Coupling and uncoupling of tumor immunity and autoimmunity.

@en

P1433

Q36375693-217CDFFB-381F-4EEA-9651-58BE28415280

P1476

Q36375693-DF9AA93E-8807-4A74-984D-B49254829EBD

P2093

Q36375693-12987495-DFAA-4932-8312-6AE45DB60EE1

Q36375693-2FC69B1A-9F4A-40CD-BD2A-7557884A29C7

Q36375693-4BAA5A04-C6B0-4C9D-A894-3727B5152419

Q36375693-8BD591C8-3CD1-4280-A73F-66D9BDD7EFA5

Q36375693-AE419A9D-0AF1-4CC2-8936-11EC9C0E011E

Q36375693-B2483993-2EB8-416B-8174-8C02E21FD534

Q36375693-D2054FD3-E4F7-4D80-93E4-81CD96E7D160

Q36375693-D2DA19CE-F374-41AB-9B1E-B4E41D147806

P2860

Q36375693-0EC33923-C825-4672-8E75-8D1620B9D452

Q36375693-29F5C595-A096-41DC-AD1C-D74164F5E9E9

Q36375693-2FB1C256-AA10-409E-BA5F-52595811E5FC

Q36375693-36A8DA96-BB9F-43D4-B45E-EE6EB97B37DA

Q36375693-3F6463DB-7E99-4B2F-93F6-898E49E769CD

Q36375693-43162627-4A1C-4ED8-BF81-CFA499A1131D

Q36375693-523028C6-9467-4001-842D-D104F0DC8BEF

Q36375693-53AA4EE0-B18C-46B3-ABD0-EDB27FCEC697

Q36375693-58BCF67F-2F08-4A8B-9C73-59D486E0312B

Q36375693-60BE9959-8391-45F5-BF75-55A3C6F55248

P304

Q36375693-509557FE-D813-4803-85E1-3BFE0FA86694

P31

Q36375693-3BCB4F17-DEF1-4B16-8191-124444D1B132

P356

Q36375693-370F2DD3-EB46-49DC-BF96-EBB9C028698C

P407

Q36375693-6C6CD757-3E5C-4A18-A2A2-12E4B88C2637

P433

Q36375693-8EB7C36B-B868-4EBF-B9FB-8022F690FD6D

P478

Q36375693-04C7DEE5-7976-4941-A00B-010C9004F5C3

P577

Q36375693-1972168C-30CF-4822-8638-A11B5D7E5F73

P5875

Q36375693-11AE0DE1-1A8F-4D42-8A21-11E32661E80F

P698

Q36375693-7251BF16-87F8-404D-978E-30A288D5964F

P932

Q36375693-6C7F1E75-2EE6-4B3C-8612-F5FEB0A5D3B5

P356

JEM.190.11.1717

P1433

Journal of Experimental Medicine

P1476

Coupling and uncoupling of tumor immunity and autoimmunity.

@en

P2093

A N Houghton

http://www.w3.org/2001/XMLSchema#string

J D Wolchok

http://www.w3.org/2001/XMLSchema#string

J J Lewis

http://www.w3.org/2001/XMLSchema#string

N E Blachere

http://www.w3.org/2001/XMLSchema#string

R Dyall

http://www.w3.org/2001/XMLSchema#string

R Srinivasan

http://www.w3.org/2001/XMLSchema#string

W B Bowne

http://www.w3.org/2001/XMLSchema#string

W G Hawkins

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product

Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

Fc receptors are required in passive and active immunity to melanoma.

Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.

Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein

Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.

P304

1717-1722

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.190.11.1717

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

190

http://www.w3.org/2001/XMLSchema#string

P577

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236239336

http://www.w3.org/2001/XMLSchema#string

P698

10587362

http://www.w3.org/2001/XMLSchema#string

P932

2195744

http://www.w3.org/2001/XMLSchema#string